^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Antioxidant

    Related drugs:
    6d
    A Study of Acute Myocardial Infarction Using FDY-5301 (clinicaltrials.gov)
    P2, N=120, Completed, Faraday Pharmaceuticals, Inc. | Phase classification: P2a --> P2
    Phase classification
    9d
    MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, University of Edinburgh | Recruiting --> Active, not recruiting | N=206 --> 79 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    13d
    Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis (clinicaltrials.gov)
    P2, N=0, Withdrawn, University of Edinburgh | N=120 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    13d
    The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (clinicaltrials.gov)
    P2, N=60, Recruiting, UConn Health | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    13d
    Probiotic Effects in Type 2 Diabetes (clinicaltrials.gov)
    P=N/A, N=77, Completed, Ege University
    New trial
    17d
    Thermotolerance induced by non-lethal heat shock at 40 °C is activated by mitochondrial ROS and is Nrf2-dependent. (PubMed, Arch Biochem Biophys)
    Mitochondrial ROS were found to be essential in mediating Nrf2-dependent thermotolerance, because MitoQ treatment prior to exposure to 40 °C reduced Nrf2 levels and dissipated the subsequent protective effect of thermotolerance against toxicity at 42 °C. Our study demonstrates that specific sources of ROS had biologically different implications in activating Nrf2, underlining potential therapeutic targets that may contribute to thermotolerance in anticancer treatments.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    30d
    Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Aug 2025 --> Apr 2026
    Trial completion date
    30d
    NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    1m
    Composite Dietary Antioxidant Index and Metabolic Health in Overweight/Obesity in U.S. Adults (clinicaltrials.gov)
    P=N/A, N=38646, Completed, University-Town Hospital of Chongqing Medical University
    New trial
    1m
    24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome (clinicaltrials.gov)
    P3, N=80, Not yet recruiting, Nacuity Pharmaceuticals, Inc.
    New P3 trial
    1m
    INCA: PK and PD Study of NPI-001 and Cysteamine Bitartrate (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Apr 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    1m
    A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS (clinicaltrials.gov)
    P2, N=25, Completed, Lumosa Therapeutics Co., Ltd. | Unknown status --> Completed | Phase classification: P2a --> P2
    Trial completion • Phase classification